Figure 2 | Scientific Reports

Figure 2

From: Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

Figure 2

Characterization of the lead antibody (33v20064) in biochemical and in vitro assays. (a) IL-33 binding sST2 biochemical competition assay (mean ± SD of duplicate determinations). (b) Inhibition of NF-κB signalling in HUVECs (mean ± SD, n = 3). (c) Inhibition of IL-8 release in HUVECs (mean ± SD, n = 2). (d) Affinity of lead antibody for human IL-33 at concentrations of 1–256 nM, which was determined by surface plasmon resonance. For each sensorgram trace 1:1 fit lines are shown in black. Figure shows a representative dataset from four separate experiments. HUVEC, human umbilical vein endothelial cell; IL, interleukin; mAb, monoclonal antibody; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; RU, response units; SD, standard deviation.

Back to article page